Medios AG Reports Strong Growth in H1 2025

Medios AG, a leading European specialty pharma company, reports significant growth for the first half of 2025. Revenues increased by 9.3% to €991.7 million, with a notable 48.8% rise in EBITDA pre1. Organically, the EBITDA pre1 grew by 12.3%. Earnings per share almost doubled to €0.50, supported by a successful public share buyback.

The Pharmaceutical Supply segment saw revenues climb to €800.1 million, with a 15.4% rise in EBITDA pre1. The Patient-Specific Therapies segment increased revenues to €110.2 million, while International Business grew remarkably, contributing €13.8 million to EBITDA pre1.

Medios confirms its 2025 forecast, projecting a 6% revenue increase to approximately €2 billion and a 21.5% rise in EBITDA pre1. The positive outlook follows dynamic growth amid strategic initiatives focused on higher-margin products.